The Leucegene project is based on the integration of RNA expression and mutation data from the 457 primary AML specimens of the Leucegene cohort, representing the world’s largest dataset for this disease, with specimen response to chemical compounds, cytogenetics and clinical annotation.

The unique aspect of the Leucegene approach lies in transcriptome analysis of specimens grouped based on recurrent mutations, classical cytogenetics, as well as cryptic and novel fusions, and comparison to transcriptome of specimens of the entire cohort lacking these genetic markers.

Our objective is to derive subgroup-specific expression signatures for precision medicine.